Redsense Medical (REDS) Q1 2025 earnings summary

Executive summary

• Q1 2025 focused on restructuring, market analysis, and team strengthening to support future growth.

• US remains the primary market, accounting for 96% of net sales.

• Redsense Clamp nearing commercial launch, with clinical validation and regulatory steps underway.

• Product development includes combining alarm and dongle, and improving optical fiber cable.

Financial highlights

• Net sales rose 179% year-over-year to KSEK 4,776 (1,711).

• Gross margin was 46%, down from 63% in Q1 2024.

• Operating loss (EBIT) was KSEK -3,152, compared to -2,656 last year.

• Result after tax was KSEK -3,152 (vs. -2,640).

• Cash and cash equivalents at period end were KSEK 16,011 (3,771).

Outlook and guidance

• Q2 2025 expected to benefit from groundwork laid in Q1, with Clamp launch and targeted sales activities.

• Ongoing monitoring of tariffs and currency volatility; sufficient inventory to meet short-term demand.

• Focus on compliance with upcoming sustainability reporting requirements.